Search clinical trials for: Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS)

Total 471327 results

Otsuka Pharmaceutical Development & Commercialization...
Bill and Melinda Gates Foundation

Completed

A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis

Pulmonary TB

South Africa
Bill & Melinda Gates Medical Research Institute
Global Alliance for TB Drug Development; Janssen Pharmaceutica; Otsuka Pharmaceutical...

Recruiting

Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis

Pulmonary Tuberculosis

South Africa, Philippines
Otsuka Pharmaceutical Development & Commercialization...
Bill and Melinda Gates Foundation

Active, not recruiting

Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB

Pulmonary TB

South Africa
Oregon Health and Science University
Hanoi Medical University; Hennepin Healthcare Research Institute

Completed

Buprenorphine to Improve HIV Care Engagement and Outcomes (BRAVO)

HIV | Substance Related Disorders

Vietnam
US Department of Veterans Affairs

Withdrawn

Comparison of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease

Parkinson's Disease

United States
Subhajit Chakravorty

Completed

The Effects of Quetiapine (Seroquel XR) on Sleep During Alcohol Abstinence

Alcoholism | Sleep Initiation and Maintenance Disorders

United States
Otsuka Pharmaceutical Co., Ltd.

Recruiting

A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])

Cardiac Edema (CHF)

Japan
Kyowa Kirin Co., Ltd.

Completed

A Study of OPC-262 in Patients With Type 2 Diabetes

Diabetes Type 2

Japan
Regina Elena Cancer Institute
University of California, San Diego; Lega Italiana per la Lotta contro i Tumori

Recruiting

New Prognostic and Predictive Biomarkers for HPV-associated Oropharyngeal Cancer

PREDICTIVE BIOMARKERS | Evaluation of HPV-specific E5 Transcript Expression in a Cohort of Patients With HPV-associated OPC | HPV 16 Positive Oropharyngeal Tumors (OPC)

Italy
Eye & ENT Hospital of Fudan University

Recruiting

An Observational Study of Clinical Treatments for Patients With Oropharyngeal Carcinoma

Oropharynx Carcinoma

China
Otsuka Pharmaceutical Co., Ltd.

Completed

Study of Aripiprazole in Patients With Schizophrenia- Effects on Glucose Metabolism-

Schizophrenia

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]

Autosomal Dominant Polycystic Kidney Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Recruiting

Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma (MM)

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-term Trial of OPC-34712 in Patients With Schizophrenia

Schizophrenia

Japan
Otsuka Pharmaceutical Development & Commercialization...

Completed

Multicenter, Open-label, Safety and Tolerability Study (STEP 210)

Schizophrenia

United States, Bulgaria, Philippines, Romania, Russian Federation, Serbia, Croatia, India, Korea, Republic of, Slovakia, Taiwan, Ukraine
Otsuka Pharmaceutical Co., Ltd.

Completed

Late Phase 2 Study of OPC-12759 Ophthalmic Suspension

Dry Eye Syndromes

Japan
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia (ZENITH)

Schizophrenia

Korea, Republic of, United States, Philippines, Malaysia, Croatia, Serbia, Russian Federation, Ukraine, Romania, Puerto Rico, Colombia, Turkey, Poland, Taiwan, Canada, Latvia, Slovakia, Mexico, Japan
Kyowa Kirin Co., Ltd.

Completed

Along-term Study of OPC-262 in Patients With Type 2 Diabetes

Diabetes, Type 2

Japan
Kyowa Kirin Co., Ltd.

Completed

A Study of OPC-262 in Patients With Type 2 Diabetes

Type 2 Diabetes

Japan
Otsuka Pharmaceutical Co., Ltd.

Terminated

A Dose-finding Study of OPC-6535 in Patients With Active Ulcerative Colitis

Colitis, Ulcerative

Japan
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Study Evaluating the of OPC-34712 in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Positron Emission Tomagraphy (PET) Study Following a Single Oral Dose of OPC-34712

Schizophrenia
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Single-blind, Placebo-controlled, Outpatient Trial to Assess the Effects of Single Oral Tablet Dose of OPC-214870

Epilepsy

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia (BEACON)

Acute Schizophrenia

United States, Philippines, Taiwan, Russian Federation, Croatia, Colombia, Mexico, Slovakia
Dorothy Kessler

Completed

Creating Satisfying Engagement in Daily Life Through Coaching for People With Multiple Sclerosis

Quality of Life | Multiple Sclerosis

Canada
Wake Forest University Health Sciences

Completed

Flavonoid Supplementation and Endothelial Function

Healthy
Otsuka Pharmaceutical Co., Ltd.

Completed

To Investigate the Efficacy and Safety of OPC-6535 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease

China, Japan, Korea, Republic of
Otsuka Pharmaceutical Co., Ltd.

Completed

Dose-response Study of OPC-12759 Ophthalmic Suspension

Dry Eye Syndromes

Japan
Otsuka Frankfurt Research Institute GmbH

Completed

Safety, Efficacy and Pharmacokinetics of OPC-67683 in Patients With Pulmonary Tuberculosis

Pulmonary Tuberculosis

South Africa
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase I, Open-Label Trial to Assess the Absorption, Metabolism, and Excretion of (14C)-OPC-61815 in Healthy Male Japanese Subjects

Healthy Adult Male

United Kingdom
Otsuka Pharmaceutical Co., Ltd.

Completed

Safety Trial of OPC-61815 Injection in Patients With Congestive Heart Failure Who Have Difficulty With or Are Incapable of Oral Intake

Congestive Heart Failure

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Dose-finding and Confirmatory Trial of OPC-6535 in Patients With Active Crohn's Disease

Crohn's Disease

Korea, Republic of, Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia

Schizophrenia

Japan
Otsuka Pharmaceutical Development & Commercialization...

Completed

Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects

Schizophrenia | Psychiatric Disorders

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 2 Trial of OPC-64005 for Major Depressive Disorder

Major Depressive Disorder

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Dose-defining Study of OPC-41061 in Treatment of Hepatic Edema

Cirrhosis

Japan
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia

Nervous System Diseases | Schizophrenia | Mental Disorder

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis

Pain Due to Osteoporosis

Japan
Kyowa Kirin Co., Ltd.

Completed

A Phase 3 Study of OPC-262 in Patients With Type 2 Diabetes

Diabetes, Type 2

Japan
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation (CADENCE 215)

Atrial Fibrillation | Paroxysmal Atrial Fibrillation | Persistent Atrial Fibrillation

United States, Italy, Germany, Netherlands, Spain, United Kingdom
Ottawa Hospital Research Institute
University of Ottawa

Completed

Occupational Performance Coaching for Stroke Survivors

Stroke

Canada
Otsuka Pharmaceutical Co., Ltd.

Terminated

A Dose-finding Study of OPC-6535 in Patients With Active Crohn's Disease

Crohn Disease

Japan
Otsuka Pharmaceutical Development & Commercialization...

Completed

FACTS I: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis

Ulcerative Colitis

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683

Tuberculosis, Multidrug-Resistant

Korea, Republic of, China, Estonia, Latvia, Peru, Philippines
Otsuka Pharmaceutical Development & Commercialization...

Completed

FACTS II: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis

Ulcerative Colitis

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

A Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic Edema

Cirrhosis

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic Edema

Cirrhosis

Japan
Sir Salimullah Medical College Mitford Hospital

Recruiting

Outcome of Moderate Severity in OPC Poisoning Patients When Treated With Pralidoxime (OPC)

Organophosphorus Poisoning

Bangladesh
Otsuka Beijing Research Institute

Completed

OPC-61815 in Healthy Chinese Male Subjects

Healthy Adult Male

China
The Hong Kong Polytechnic University
University of Otago; Food and Health Bureau, Hong Kong; National Cheng Kung University

Recruiting

Occupational Performance Coaching With Parents of Young Children With Developmental Disability

Developmental Disability

Hong Kong

Search clinical trials for: Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations